- Telehealth Visits
- Insurance plan information
Jeffrey A. Golden, MD
Chronic Obstructive Pulmonary Disease • Interstitial Lung DiseaseAssociate Medical Director, Lung Transplant Program- Telehealth Visits
- Insurance plan information
Jeffrey A. Golden, MD
Chronic Obstructive Pulmonary Disease • Interstitial Lung DiseaseAssociate Medical Director, Lung Transplant Program- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Jeffrey Golden, associate medical director of the UCSF Lung Transplant Program, is a pulmonologist who cares for patients with severe lung disease, particularly those who are candidates for lung transplants.
Golden is director of clinical trials (studies to evaluate new therapies) for the Interstitial Lung Disease Program. In 2010, one of his longtime patients, Nina Ireland, left $48 million – almost her entire estate – to UCSF, creating the Nina Ireland Program for Lung Health. The ambitious program supports creative, collaborative approaches to advancing patient care, professional training and research in pulmonary medicine.
Golden earned his medical degree at Washington University in St. Louis. He completed his training in both internal medicine and pulmonary medicine at UCSF. He completed pulmonary research training at the UCSF Cardiovascular Research Institute, where he studied ozone inhalation in humans as a model of asthma.
Education & training
Board certification
- Pulmonary Disease, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Degree
- MD, Washington University
My expertise
Specialties
- Chronic Obstructive Pulmonary Disease
- Interstitial Lung Disease
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Connective Tissue Lung Disease
- Sarcoidosis
- Pulmonary Fibrosis
- Hypersensitivity Pneumonitis
Locations
My work
A cystic fibrosis patient who was out of options
My research
Clinical trials
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)Opens in a new window
Recruiting
To demonstrate a reduction in lung function decline for ifetroban compared to placebo over 52 weeks.
Publications
Showing 1-6 of 7 reviews
- July 11, 20253.8 out of 5 Stars
Provider seemed to be unprepared for my appt. Wasn't aware of recent hospital stay and needed reason.
- April 6, 20255 out of 5 Stars
DR Golden really made me feel like I was his only patient and that he was really concerned about my health.
- February 1, 20255 out of 5 Stars
Provider displayed great bedside manner and listened my thoughts and opinions.
- October 5, 20245 out of 5 Stars
Dr. Golden was excellent!
- June 3, 20245 out of 5 Stars
The meeting began on time. The care provider was very thorough and attentive. She provided great information that was relevant and informative. She answered all of our questions, and she made us feel like our case was important.
- May 16, 20245 out of 5 Stars
Dr Golden was great!
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.